We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tetraphase Pharmaceuticals Inc | NASDAQ:TTPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.22 | 2.31 | 0 | 01:00:00 |
– Four Abstracts Selected for Poster Presentations –
The details for the data presentations at IDWeek are as follows:
XERAVA Poster Presentations
Poster title: Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal InfectionsDate and time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m. PTLocation: S Poster HallPoster number: 1976Session information: Poster Abstract Session: Clinical Trials
Poster title: Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 Studies of Complicated Intra-Abdominal InfectionsDate and time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m. PTLocation: S Poster HallPoster number: 1978Session information: Poster Abstract Session: Clinical Trials
Poster title: Combined Microbiological Response Rates from Two Phase 3 Trials Demonstrating the Activity of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4Date and time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m. PTLocation: S Poster HallPoster number: 1963Session information: Poster Abstract Session: Clinical Trials
TP-6076 Oral Presentation
Presentation title: TP-6076 – Tetraphase PharmaceuticalsDate and time: Thursday, October 4 from 2:00 p.m. – 3:15 p.m. PTLocation: N Hall DPresentation number: 837Speaker: Larry Tsai, M.D. Session information: Exploring the Antibiotic Pipeline 2018
TP-6076 Poster Presentation
Poster title: Safety, Tolerability and Pharmacokinetics of Multiple Doses of TP-6076, a Novel, Fully Synthetic Tetracycline, in a Phase 1 StudyDate and time: Friday, October 5 from 12:30 p.m. – 1:45 p.m. PTLocation: S Poster HallPoster number: 1371Session information: Poster Abstract Session: Novel Agents
Additional Activities
IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Full abstracts can be found on the IDWeek website at http://www.idweek.org/
About XERAVA™ XERAVA (eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.
Important Safety Information
To report suspected adverse reactions, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full prescribing information for XERAVA at www.XERAVA.com.
About Tetraphase Pharmaceuticals, Inc.Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product XERAVA™ is approved for the treatment of complicated intra-abdominal infections (cIAI) by the U.S. Food and Drug Administration and under review for marketing application authorization approval by the European Commission for the treatment of cIAI. The Company’s pipeline also includes TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Forward-Looking StatementsAny statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether eravacycline will be successfully distributed and marketed and other regulatory and commercial risk factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the period ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018. In addition, the forward-looking statements included in this press release represent our views as of September 19, 2018. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.
Media and Investor Contact:Tetraphase PharmaceuticalsJennifer Viera617-600-7040jviera@tphase.com
1 Year Tetraphase Pharmaceuticals Chart |
1 Month Tetraphase Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions